| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 66 | 2025 | 703 | 5.980 |
Why?
|
| Lung | 17 | 2023 | 966 | 1.230 |
Why?
|
| Respiratory Function Tests | 16 | 2021 | 195 | 1.010 |
Why?
|
| Pulmonary Emphysema | 10 | 2018 | 109 | 0.870 |
Why?
|
| Smoking | 16 | 2018 | 862 | 0.790 |
Why?
|
| Exercise Tolerance | 13 | 2016 | 85 | 0.780 |
Why?
|
| Asthma | 6 | 2023 | 483 | 0.780 |
Why?
|
| Exercise Test | 10 | 2015 | 257 | 0.740 |
Why?
|
| Biomarkers | 13 | 2020 | 1480 | 0.740 |
Why?
|
| Forced Expiratory Volume | 16 | 2020 | 212 | 0.660 |
Why?
|
| Aged | 55 | 2025 | 14965 | 0.620 |
Why?
|
| Spirometry | 10 | 2022 | 113 | 0.600 |
Why?
|
| Quality of Life | 12 | 2023 | 1260 | 0.600 |
Why?
|
| Metabolomics | 1 | 2019 | 63 | 0.590 |
Why?
|
| Severity of Illness Index | 15 | 2018 | 1559 | 0.590 |
Why?
|
| Energy Metabolism | 1 | 2019 | 399 | 0.490 |
Why?
|
| Middle Aged | 49 | 2025 | 18273 | 0.490 |
Why?
|
| Male | 61 | 2025 | 31047 | 0.470 |
Why?
|
| Cytokines | 2 | 2012 | 952 | 0.460 |
Why?
|
| Female | 62 | 2025 | 34018 | 0.450 |
Why?
|
| Cohort Studies | 17 | 2021 | 2620 | 0.440 |
Why?
|
| Walking | 8 | 2015 | 245 | 0.430 |
Why?
|
| Humans | 79 | 2025 | 65140 | 0.430 |
Why?
|
| Hospitalization | 9 | 2023 | 1392 | 0.430 |
Why?
|
| Vascular Calcification | 3 | 2025 | 27 | 0.420 |
Why?
|
| Pulmonary Diffusing Capacity | 3 | 2021 | 18 | 0.400 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2012 | 65 | 0.380 |
Why?
|
| Lung Diseases, Obstructive | 2 | 2014 | 34 | 0.370 |
Why?
|
| Prospective Studies | 16 | 2019 | 3308 | 0.350 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2012 | 234 | 0.350 |
Why?
|
| Exercise Therapy | 1 | 2012 | 102 | 0.340 |
Why?
|
| Genome-Wide Association Study | 3 | 2018 | 361 | 0.330 |
Why?
|
| Medicare | 5 | 2023 | 625 | 0.330 |
Why?
|
| Carbon Monoxide | 3 | 2021 | 63 | 0.310 |
Why?
|
| Coronary Artery Disease | 2 | 2025 | 324 | 0.310 |
Why?
|
| ADAM Proteins | 2 | 2020 | 36 | 0.300 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 702 | 0.300 |
Why?
|
| Disease Progression | 11 | 2019 | 1220 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 730 | 0.290 |
Why?
|
| Respiratory Therapy | 2 | 2018 | 10 | 0.280 |
Why?
|
| Body Mass Index | 10 | 2018 | 897 | 0.270 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2018 | 43 | 0.270 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2023 | 144 | 0.250 |
Why?
|
| Comorbidity | 8 | 2022 | 1119 | 0.250 |
Why?
|
| Hand Strength | 3 | 2015 | 34 | 0.250 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 1113 | 0.250 |
Why?
|
| Interleukin-6 | 4 | 2013 | 324 | 0.240 |
Why?
|
| Exome | 2 | 2016 | 69 | 0.240 |
Why?
|
| Adult | 23 | 2023 | 17358 | 0.230 |
Why?
|
| Pneumonia | 2 | 2021 | 291 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2025 | 1656 | 0.230 |
Why?
|
| Epithelial Cells | 2 | 2020 | 413 | 0.220 |
Why?
|
| Risk Assessment | 6 | 2025 | 2102 | 0.220 |
Why?
|
| Coronary Vessels | 1 | 2025 | 125 | 0.220 |
Why?
|
| Smokers | 3 | 2021 | 117 | 0.210 |
Why?
|
| Chemokines, CC | 3 | 2013 | 12 | 0.210 |
Why?
|
| Cardiovascular Diseases | 2 | 2025 | 863 | 0.210 |
Why?
|
| Proteomics | 1 | 2006 | 293 | 0.210 |
Why?
|
| Uteroglobin | 2 | 2015 | 7 | 0.210 |
Why?
|
| Oxygen Consumption | 3 | 2011 | 213 | 0.200 |
Why?
|
| Membrane Proteins | 2 | 2020 | 919 | 0.200 |
Why?
|
| Early Detection of Cancer | 3 | 2023 | 325 | 0.200 |
Why?
|
| Survival Rate | 4 | 2019 | 844 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 767 | 0.190 |
Why?
|
| Risk Factors | 12 | 2025 | 5429 | 0.190 |
Why?
|
| Patient Preference | 1 | 2023 | 86 | 0.190 |
Why?
|
| Beclomethasone | 1 | 2022 | 1 | 0.180 |
Why?
|
| Macrophages, Alveolar | 2 | 2020 | 65 | 0.180 |
Why?
|
| Prognosis | 9 | 2015 | 1784 | 0.180 |
Why?
|
| Vital Capacity | 7 | 2020 | 122 | 0.180 |
Why?
|
| Interleukin-8 | 3 | 2012 | 96 | 0.170 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2022 | 49 | 0.170 |
Why?
|
| Case-Control Studies | 7 | 2020 | 1141 | 0.170 |
Why?
|
| Pneumonectomy | 3 | 2015 | 130 | 0.170 |
Why?
|
| Patient Readmission | 2 | 2023 | 451 | 0.170 |
Why?
|
| Glucocorticoids | 1 | 2022 | 189 | 0.160 |
Why?
|
| Follow-Up Studies | 10 | 2017 | 2483 | 0.160 |
Why?
|
| Bronchi | 1 | 2020 | 85 | 0.160 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 170 | 0.150 |
Why?
|
| Health Status | 3 | 2015 | 447 | 0.150 |
Why?
|
| United States | 10 | 2023 | 8093 | 0.150 |
Why?
|
| Survival Analysis | 6 | 2020 | 576 | 0.140 |
Why?
|
| Pulmonologists | 1 | 2018 | 5 | 0.140 |
Why?
|
| Heart Failure | 1 | 2006 | 957 | 0.140 |
Why?
|
| Telemedicine | 1 | 2023 | 362 | 0.140 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 5614 | 0.130 |
Why?
|
| Retrospective Studies | 7 | 2023 | 6872 | 0.130 |
Why?
|
| Eosinophilia | 1 | 2017 | 37 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2018 | 342 | 0.130 |
Why?
|
| Endothelium | 1 | 2017 | 21 | 0.130 |
Why?
|
| Inflammation | 2 | 2015 | 1192 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 604 | 0.130 |
Why?
|
| Dyspnea | 4 | 2013 | 120 | 0.130 |
Why?
|
| Genetic Loci | 1 | 2017 | 116 | 0.120 |
Why?
|
| Interleukin-27 | 1 | 2016 | 7 | 0.120 |
Why?
|
| Prevalence | 5 | 2022 | 1445 | 0.120 |
Why?
|
| ROC Curve | 4 | 2025 | 292 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2018 | 302 | 0.120 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 9 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 676 | 0.120 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2006 | 87 | 0.120 |
Why?
|
| Lymphoid Tissue | 1 | 2015 | 54 | 0.120 |
Why?
|
| Muscle Weakness | 1 | 2015 | 33 | 0.110 |
Why?
|
| Disease Management | 1 | 2017 | 235 | 0.110 |
Why?
|
| Interleukin-16 | 2 | 2012 | 25 | 0.110 |
Why?
|
| Spain | 4 | 2018 | 32 | 0.110 |
Why?
|
| Chemokine CCL2 | 2 | 2012 | 61 | 0.110 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2015 | 4 | 0.110 |
Why?
|
| Information Services | 1 | 2015 | 35 | 0.110 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2016 | 67 | 0.110 |
Why?
|
| Smoke | 1 | 2015 | 24 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 407 | 0.110 |
Why?
|
| Kidney | 1 | 2017 | 451 | 0.110 |
Why?
|
| Oxygen | 1 | 2016 | 319 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 105 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 439 | 0.110 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2014 | 4 | 0.110 |
Why?
|
| Mononuclear Phagocyte System | 1 | 2014 | 3 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 801 | 0.110 |
Why?
|
| Surveys and Questionnaires | 7 | 2022 | 2757 | 0.100 |
Why?
|
| Busulfan | 1 | 2014 | 18 | 0.100 |
Why?
|
| Mexican Americans | 1 | 2014 | 14 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 496 | 0.100 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2014 | 23 | 0.100 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 101 | 0.100 |
Why?
|
| Receptors, Cell Surface | 2 | 2006 | 431 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 1630 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 140 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 415 | 0.100 |
Why?
|
| Nutrition Surveys | 1 | 2014 | 149 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2015 | 435 | 0.100 |
Why?
|
| Fibronectins | 1 | 2013 | 44 | 0.100 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 113 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 740 | 0.090 |
Why?
|
| Morbidity | 2 | 2023 | 110 | 0.090 |
Why?
|
| Puerto Rico | 2 | 2023 | 138 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 563 | 0.090 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 55 | 0.090 |
Why?
|
| Longitudinal Studies | 5 | 2014 | 1282 | 0.090 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2014 | 161 | 0.090 |
Why?
|
| Aging | 1 | 2018 | 771 | 0.090 |
Why?
|
| Time Factors | 6 | 2021 | 3762 | 0.090 |
Why?
|
| Symptom Flare Up | 2 | 2022 | 15 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 353 | 0.080 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2015 | 91 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2023 | 181 | 0.080 |
Why?
|
| Regression Analysis | 3 | 2020 | 497 | 0.080 |
Why?
|
| Bronchoscopy | 2 | 2009 | 88 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2011 | 213 | 0.070 |
Why?
|
| Stroke Volume | 1 | 2011 | 342 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 706 | 0.070 |
Why?
|
| Boston | 2 | 2020 | 258 | 0.070 |
Why?
|
| Blood Gas Analysis | 1 | 2007 | 34 | 0.070 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2007 | 43 | 0.070 |
Why?
|
| Electrocardiography | 2 | 2011 | 554 | 0.070 |
Why?
|
| Risk | 2 | 2021 | 374 | 0.060 |
Why?
|
| Hydrogels | 1 | 2009 | 127 | 0.060 |
Why?
|
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2007 | 1 | 0.060 |
Why?
|
| Leukotriene B4 | 1 | 2007 | 12 | 0.060 |
Why?
|
| Microarray Analysis | 1 | 2007 | 64 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2014 | 1326 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 213 | 0.060 |
Why?
|
| Serpins | 1 | 2006 | 18 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 930 | 0.060 |
Why?
|
| Mice | 6 | 2018 | 11119 | 0.060 |
Why?
|
| Linear Models | 1 | 2007 | 405 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2020 | 750 | 0.060 |
Why?
|
| Genetic Linkage | 1 | 2005 | 97 | 0.060 |
Why?
|
| Social Class | 2 | 2019 | 137 | 0.060 |
Why?
|
| Phenotype | 2 | 2021 | 1233 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 2293 | 0.060 |
Why?
|
| Rest | 2 | 2016 | 45 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2017 | 321 | 0.050 |
Why?
|
| Animals | 7 | 2018 | 21345 | 0.050 |
Why?
|
| Africa | 1 | 2023 | 30 | 0.050 |
Why?
|
| Sex Factors | 2 | 2021 | 992 | 0.050 |
Why?
|
| Exercise | 2 | 2020 | 964 | 0.050 |
Why?
|
| Respiratory Muscles | 1 | 2003 | 17 | 0.050 |
Why?
|
| Gene Expression | 1 | 2006 | 852 | 0.050 |
Why?
|
| Mucus | 1 | 2002 | 16 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2022 | 159 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 37 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 794 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2017 | 1015 | 0.040 |
Why?
|
| Uncertainty | 1 | 2020 | 39 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 1698 | 0.040 |
Why?
|
| Beijing | 1 | 2020 | 1 | 0.040 |
Why?
|
| England | 1 | 2020 | 28 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2020 | 23 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 3485 | 0.040 |
Why?
|
| Massachusetts | 1 | 2006 | 2145 | 0.040 |
Why?
|
| Cough | 1 | 2002 | 183 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 387 | 0.040 |
Why?
|
| Apoptosis | 2 | 2015 | 1098 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2020 | 71 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2015 | 5792 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 190 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 374 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 319 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 181 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 133 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1269 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2018 | 5 | 0.030 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 56 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2018 | 81 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 101 | 0.030 |
Why?
|
| Epigenomics | 1 | 2018 | 62 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 4809 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2003 | 788 | 0.030 |
Why?
|
| Radiography | 2 | 2010 | 555 | 0.030 |
Why?
|
| Eosinophils | 1 | 2017 | 49 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2018 | 121 | 0.030 |
Why?
|
| Algorithms | 2 | 2013 | 1050 | 0.030 |
Why?
|
| Health Surveys | 1 | 2018 | 316 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 805 | 0.030 |
Why?
|
| Walk Test | 1 | 2016 | 9 | 0.030 |
Why?
|
| Serpin E2 | 2 | 2006 | 3 | 0.030 |
Why?
|
| Protease Nexins | 2 | 2006 | 3 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 122 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2020 | 519 | 0.030 |
Why?
|
| Lod Score | 2 | 2005 | 23 | 0.030 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2015 | 1 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2015 | 16 | 0.030 |
Why?
|
| Mucin 5AC | 1 | 2015 | 9 | 0.030 |
Why?
|
| Fatigue | 2 | 2009 | 113 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 1149 | 0.030 |
Why?
|
| Pulmonary Alveoli | 1 | 2015 | 44 | 0.030 |
Why?
|
| Airway Remodeling | 1 | 2015 | 22 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2015 | 28 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 48 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 221 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2015 | 48 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 252 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2015 | 147 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 262 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1419 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 261 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 108 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 481 | 0.030 |
Why?
|
| Unrelated Donors | 1 | 2014 | 8 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 2014 | 22 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 149 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 47 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2005 | 297 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 86 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 105 | 0.030 |
Why?
|
| Pulmonary Medicine | 1 | 2014 | 41 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 293 | 0.020 |
Why?
|
| Demography | 1 | 2014 | 178 | 0.020 |
Why?
|
| Child | 1 | 2022 | 4607 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2014 | 309 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 883 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 380 | 0.020 |
Why?
|
| Florida | 1 | 2011 | 46 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 734 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1586 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 924 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2011 | 94 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2157 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 602 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1008 | 0.020 |
Why?
|
| Leukocytosis | 1 | 2009 | 15 | 0.020 |
Why?
|
| Fever | 1 | 2009 | 65 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 1163 | 0.020 |
Why?
|
| Residual Volume | 1 | 2007 | 4 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 198 | 0.010 |
Why?
|
| Haplotypes | 1 | 2005 | 134 | 0.010 |
Why?
|
| Inspiratory Capacity | 1 | 2004 | 2 | 0.010 |
Why?
|
| Total Lung Capacity | 1 | 2004 | 14 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 2004 | 52 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 896 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 542 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 509 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2003 | 50 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2003 | 101 | 0.010 |
Why?
|
| Maximal Midexpiratory Flow Rate | 1 | 2002 | 3 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2002 | 46 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2003 | 209 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2002 | 342 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 1574 | 0.010 |
Why?
|